CLINICAL THERAPIES
Five investigational immunotherapies targeting a range of types of cancers.
Axalimogene Filolisbac
ADXS-DUAL
Advaxis’ lead Lm Technology™ immunotherapies axalimogene filolisbac and ADXS-DUAL target HPV-associated cancers and are in clinical trials for four potential indications.
ADXS-PSA
ADXS-PSA is under investigation for targeting the prostate-specific antigen (PSA) associated with prostate cancer and is in clinical development both as a monotherapy and in combination with immune checkpoint inhibitors for the treatments of metastatic castration-resistant prostate cancer (mCRPC).
ADXS-HER2
Advaxis is developing ADXS-HER2 to target human epidermal growth factor receptor 2 (HER2)-expressing cancers. HER2 is expressed in certain solid-tumor cancers, including some breast, gastric, and esophageal cancers and osteosarcoma.
NEOANTIGENS
Taking advantage of recent advances in genome sequencing with the capacity to target all of a patient’s immunogenic cancer neoepitopes, Advaxis’ has two candidates utilizing neoepitopes:
ADXS-NEO (in partnership with Amgen)
ADXS-HOT
Partnerships
PARTNERS
Advaxis has established clinical partners for its proprietary Lm Technology™ immunotherapies with numerous biopharmaceutical industry leaders.
LICENSING AGREEMENTS
Advaxis has exclusively licensed certain constructs of its Lm Technology™ proprietary immunotherapies to numerous biopharmaceutical industry leaders for both human and animal therapeutics.
INSTITUTIONS AND FOUNDATIONS
Advaxis has also fostered strong partners with the multiple academic institutions and foundations for the development of its clinical pipeline.